This column presents principles that will aid the prescriber in transitioning patients from an oral to a depot antipsychotic medication. The column covers the differences in the pharmacokinetics of oral versus depot formulations that are critical in making a smooth transition. Also discussed are some of the reasons to use these medications, which, in the author’s opinion, are currently underutilized. This column focuses on the big picture and the fundamentals of oral versus depot formulations rather than comparing the relative merits or potential advantages of the various marketed depot formulations.
PRESKORN: Kansas University School of Medicine-Wichita, Wichita, KS
S.H.P. has worked with over 130 pharmaceutical companies in the United States and throughout the world. Over the past year, he has received grants/research support from or has served as a consultant, on the advisory board, or on the speaker’s bureau for Acadia, Alkermes, Assurex Health (developer and marketer of the GeneSight test), BioXcel, Food and Drug Administration, Eisai, Forum, Janssen, National Institute of Mental Health, Merck, Naurex/Aptinyx, Novaritis, Rugen Holdings, The Stanley Medical Research Institute, Sunovion, and Vanda. Specific to this column, S.H.P. was a consultant to Alkermes on the educational programs for prescribers on the principles underlying the transition from oral to depot antipsychotics and on new drug development.
Please send correspondence to: Sheldon H. Preskorn, MD, University of Kansas Medical Center, 1010 N. Kansas, Wichita, KS 67217.